Grail’s Galleri multi-cancer early detection trial misses primary endpoint, but oncologists note promising signals

The first randomized trial of a multi-cancer early detection test enrolled about 143,000 English adults aged 50 to 77. Participants were randomly assigned to receive either standard care or the Galleri MCED test, with three rounds of annual molecular screening. The study’s primary goal was to lower the incidence of stage 3 and 4 cancers across all tumor types, but the endpoint was not achieved.

Even though the trial did not demonstrate a reduction in late‑stage cancers, the author, an oncologist and researcher, highlights several encouraging observations. She points to early‑stage detections and other signals that suggest the technology may have value, but notes that technical and methodological issues limited the ability to draw firm conclusions.

The results were presented at the American Society of Clinical Oncology meeting in Chicago, reflecting a partnership between the U.K. National Health Service and Grail. The oncologist also references forthcoming guidance from the American Cancer Society, indicating that the field will continue to evaluate how best to integrate such tests into cancer screening strategies.